K Ng

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
    Clin Cancer Res 19:3987-95. 2013
  2. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
  3. pmc Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
    Y Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 102:1422-7. 2010

Detail Information

Publications3

  1. pmc Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
    Clin Cancer Res 19:3987-95. 2013
    ..Everolimus, an oral inhibitor of mTOR, showed efficacy in patients with metastatic colorectal cancers in phase I studies...
  2. pmc Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
    K Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 101:916-23. 2009
    ....
  3. pmc Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies
    Y Bao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Br J Cancer 102:1422-7. 2010
    ..Studies evaluating vitamin D status in relation to pancreatic cancer risk have yielded inconsistent results...